TFRC and cancer: In order to improve the intratumor delivery and active targeting of drugs, especially for drugs targeting cancer cells, the surface of nanocarriers can be modified with various receptor-targeting ligands (such as, FR, TfR, HA, etc.) to specifically bind to the receptors on the surface membrane of cancer cells.